| Dec'19 | Dec'18 | Dec'17 | Dec'16 | Dec'15 | Dec'14 | |
|---|---|---|---|---|---|---|
Operating activities | ||||||
Net income (loss) | ||||||
89,833 | -209,409 | -238,286 | -127,788 | -223,938 | -87,177 | |
Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities: | ||||||
Depreciation and amortization | ||||||
3,300 | 3,200 | 3,400 | 2,996 | 1,869 | 674 | |
Remeasurement of fair-value contingent consideration | ||||||
42 | -3,230 | -2,260 | 4,305 | 4,599 | 5,185 | |
Provision for other receivables | ||||||
- | - | - | -1,300 | 1,300 | - | |
Stock-based compensation expense | ||||||
33,591 | 34,797 | 33,397 | 27,421 | 16,721 | 11,062 | |
Non-cash accretion of discount on marketable securities | ||||||
165 | 301 | 156 | - | - | - | |
Remeasurement of convertible preferred stock warrant and embedded derivative liabilities | ||||||
- | - | - | - | - | 15,899 | |
Preferred stock issued in exchange for services | ||||||
- | - | - | - | - | 147 | |
Non-cash interest expense from amortization of debt discount | ||||||
2,339 | 1,484 | 1,352 | 1,041 | -38 | 3,897 | |
Gain on extinguishment of 2013 Notes | ||||||
- | - | - | - | - | 2,048 | |
Impairment of property and equipment | ||||||
-110 | -3,861 | -558 | - | -382 | - | |
Excess and obsolete inventory | ||||||
400 | 0 | 0 | - | - | - | |
Non-cash manufacturing postponement fee settled in common stock | ||||||
0 | 0 | 4,125 | - | - | - | |
Non-cash operating lease expense | ||||||
1,789 | 0 | 0 | - | - | - | |
Upfront and milestone expense related to license and collaboration arrangements | ||||||
11,075 | 0 | 0 | - | - | - | |
Changes in operating assets and liabilities: | ||||||
Trade receivables, net | ||||||
141,992 | 0 | 0 | - | - | - | |
Receivables from collaboration and license agreement | ||||||
0 | 0 | -1,859 | 299 | -857 | 2,139 | |
Inventory | ||||||
48,184 | 5,484 | 0 | - | - | - | |
Notes receivable | ||||||
- | - | - | - | -1,853 | 1,815 | |
Notes receivable from related parties | ||||||
- | - | - | - | - | -107 | |
Prepaid manufacturing | ||||||
672 | -7,063 | -7,788 | 16,119 | 14,288 | 14,692 | |
Other prepaid and current assets | ||||||
2,126 | -1,146 | -11,014 | - | - | - | |
Other prepaid assets | ||||||
- | - | - | -19,246 | - | - | |
Other assets | ||||||
- | - | - | -1,111 | 3,329 | 2,046 | |
Other assets - related party | ||||||
- | - | - | - | -1,691 | 1,691 | |
Other assets, non-current | ||||||
348 | 1 | 0 | -88 | -42 | 25 | |
Accounts payable | ||||||
9,893 | -301 | -3,810 | -4,965 | 18,404 | 3,629 | |
Accounts payable - related parties | ||||||
0 | -233 | -644 | -2,671 | 1,528 | 1,637 | |
Accrued rebates, fees and reserve | ||||||
51,120 | 0 | 0 | - | - | - | |
Accrued compensation | ||||||
10,035 | 8,466 | -4,871 | 2,279 | - | - | |
Accrued and other liabilities | ||||||
10,386 | 69 | -14,079 | - | - | - | |
Lease liabilities | ||||||
-2,010 | 0 | 0 | - | - | - | |
Accrued liabilities | ||||||
- | - | - | 1,674 | 12,832 | 3,949 | |
Other liabilities | ||||||
- | - | - | 65 | -28 | 31 | |
Deferred revenue | ||||||
0 | 0 | -1,562 | -93,236 | 32,294 | 19,848 | |
Advance payments under license agreements | ||||||
0 | 0 | -1,070 | -260 | 138 | 1,192 | |
Contingent liability to collaborator | ||||||
- | - | - | -66,255 | 38,605 | 20,150 | |
Other liabilities, non-current | ||||||
-30 | -428 | 242 | 128 | 516 | 299 | |
Net cash provided by (used in) operating activities | ||||||
28,355 | -159,266 | -200,286 | -252,545 | -107,990 | -23,927 | |
Net cash acquired from acquisition of InteKrin Therapeutics Inc. | ||||||
- | - | - | - | - | 2,334 | |
Purchases of property and equipment | ||||||
1,822 | 789 | 4,573 | 6,515 | 6,164 | 2,849 | |
Purchases of investments in marketable securities | ||||||
20,235 | 42,869 | 74,344 | - | - | - | |
Proceeds from maturities of investments in marketable securities | ||||||
20,400 | 43,170 | 74,500 | - | - | - | |
Upfront and milestone payments related to license and collaboration arrangements | ||||||
11,075 | 0 | 0 | - | - | - | |
Purchase of non-controlling interest related to InteKrin Russia | ||||||
0 | 300 | 0 | - | - | - | |
Purchase of non-controlling interest related to InteKrin Russia - related party | ||||||
0 | 400 | 0 | - | - | - | |
Net cash used in investing activities | ||||||
-12,732 | -1,188 | -4,417 | -6,515 | -6,949 | -525 | |
Financing activities | ||||||
Proceeds from common stock offering, net of underwriters discounts, commissions and offering costs | ||||||
8,153 | 101,748 | 131,305 | 123,606 | - | - | |
Increase in restricted cash | ||||||
- | - | - | - | 785 | 10 | |
Proceeds from issuance of convertible preferred stock, net of issuance costs | ||||||
- | - | - | - | - | 54,660 | |
Proceeds from issuance of convertible notes | ||||||
- | - | - | 75,000 | - | - | |
Proceeds from issuance of convertible notes - related parties | ||||||
- | - | - | 25,000 | - | - | |
Proceeds from issuance of convertible preferred stock upon exercise of warrants | ||||||
- | - | - | - | - | 131 | |
Proceeds from initial public offering, net of underwriters discounts and commissions | ||||||
- | - | - | - | - | 85,419 | |
Proceeds from follow-on offering, net of underwriters discounts and commissions | ||||||
- | - | - | - | 112,800 | - | |
Proceeds from private placement | ||||||
0 | 0 | 75,000 | - | 10,000 | - | |
Proceeds from term loan, net of issuance costs | ||||||
72,955 | 0 | 0 | - | - | - | |
Proceeds from issuances of common stock upon exercise of stock options | ||||||
5,558 | 2,082 | 482 | 3,312 | 1,429 | 55 | |
Payments of convertible notes issuance costs | ||||||
- | - | - | 739 | - | - | |
Proceeds from purchase under the employee stock purchase plan | ||||||
3,519 | 1,591 | 0 | - | - | - | |
Taxes paid related to net share settlement of bonus payout in RSUs | ||||||
815 | 0 | 0 | - | - | - | |
Net cash provided by financing activities | ||||||
89,370 | 105,421 | 206,787 | 226,179 | 122,689 | 135,956 | |
Repurchase of restricted common stock | ||||||
- | - | - | - | - | 2 | |
Effect of exchange rate changes in cash, cash equivalents and restricted cash | ||||||
-276 | 468 | -120 | -398 | 84 | -666 | |
Net increase in cash, cash equivalents and restricted cash | ||||||
104,717 | -54,565 | 1,964 | -33,279 | 7,834 | 110,838 | |
Supplemental disclosure of cash flow information | ||||||
Loss (gain) on disposal of property and equipment | ||||||
0 | 0 | -51 | 6 | - | - | |
Non-cash bonus payment settled in common stock | ||||||
0 | 0 | 2,668 | - | - | - | |
Cash paid for interest | ||||||
15,263 | 8,200 | 8,200 | 6,939 | 33 | 1 | |
Cash paid for income taxes | ||||||
1,732 | 0 | 0 | - | - | - | |
Supplemental disclosures of non-cash investing and financing activities | ||||||
Contingent consideration accrued in connection with acquisition | ||||||
- | - | - | - | - | 1,310 | |
Reclassification of fair value of convertible preferred stock warrants to preferred stock upon exercise | ||||||
- | - | - | - | - | 40,150 | |
Purchase of property and equipment in accounts payable and accrued liabilities | ||||||
999 | 272 | 77 | 507 | 1,684 | 726 | |
Non-cash non-controlling interest reflected in additional paid in capital | ||||||
0 | 1,359 | 0 | - | - | - | |
Right-of-use assets obtained in exchange for lease obligations related to operating leases | ||||||
5,267 | 0 | 0 | - | - | - | |
Non-cash employee bonuses settled in common stock | ||||||
1,350 | 0 | 2,668 | - | - | - | |
Leasehold improvements allowance from landlord | ||||||
- | - | - | - | 1,239 | - | |
Initial public offering costs in accounts payable | ||||||
- | - | - | - | - | 855 | |
Costs related to future offerings in accounts payable and accrued liabilities | ||||||
- | - | - | - | 124 | - | |
Common stock offering costs in accounts payable and accrued liabilities | ||||||
0 | 75 | 115 | 39 | - | - | |
Manufacturing services settled in common stock | ||||||
0 | 0 | 6,810 | - | - | - | |
Accrued expenses settled in common stock warrants | ||||||
- | - | - | - | - | 55 | |
Accrued expenses settled in preferred stock | ||||||
- | - | - | - | - | 10 | |
Fair value of contingent consideration settled in common stock | ||||||
- | - | - | - | 9,849 | - | |